Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
MIAMI, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer,...
-
MIAMI, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer,...
-
--Q1 FY21 Net Revenues and Gross Profit of $15M and $11M, Respectively, Achieve New Historical Highs for Second Consecutive Quarter-- --Late Clinical Stage Oncology Drug Pipeline Focused on Prostate...
-
– Potential for two-pronged action against COVID-19 as an antiviral and anti-inflammatory agent supported by Phase 2 clinical study results – – Primary efficacy endpoint in...
-
MIAMI, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer,...
-
--International Study Establishes the Role of Androgen Receptor as a Tumor Suppressor in ER+ Advanced Breast Cancer-- --Preclinical Studies Support Enobosarm’s Novel Mechanism of Action as an AR...
-
MIAMI, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer,...
-
-- Phase 2 Multicenter, International Clinical Study Selected as Spotlight Presentation at 2020 San Antonio Breast Cancer Symposium – --Enobosarm Demonstrated Clinically Meaningful Clinical Benefit...
-
-- Preclinical Data Presented at the 2020 San Antonio Breast Cancer Symposium-- -- VERU-111 has Anticancer Activity in Both Paclitaxel Sensitive and Paclitaxel Resistant Triple Negative Breast...
-
--Transformation to Premium Oncology Biopharmaceutical Company with Late-Stage Clinical Drug Pipeline Focused on Prostate and Breast Cancer is Complete-- --Company Poised to Initiate Four...